Oyman Abdilkerim1, Ozcelik Melike1, Basak Mustafa2, Gokyer Ali3, Mahmut Emre Yildirim4
1University of Health Sciences, Umraniye Education and Research Hospital, Istanbul, Turkey.
2Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
3Division of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, Turkey.
4Dr. Lutfi Kırdar, Kartal Education and Research Hospital, Istanbul, Turkey.
Summary
Purpose: To investigate the efficacy and safety of pazopanib in the first-line treatment of metastatic renal cell carcinoma in an everyday oncology practice population.
Methods: Patients aged 18 years and older and histopathologically diagnosed with renal cell carcinoma between 2012 and 2020 were included in the study. All patients received pazopanib treatment at a daily dose of 800 mg. Radiological response was assessed every 12 weeks using abdominal and thoracic CT. The side effects were graded using National Cancer Institute Criteria (CTCAE v4.).
Results: A total of 84 patients were included. The median age was 61 years (range: 37-87). There were 59 (70.2%) males and 25 (29.8%) females. The objective response rate (ORR: CR + PR) was 26.6%, while the disease control rate (DCR: CR + PR + SD) was 77.4%. Median progression-free survival (PFS) was 14.4 months (95%Cl, 8.0-20.7). The median overall survival (mOS) was 23.9 months (95%CI, 5.9-41.8). When compared, the MSKCC favorable group had a median OS of 37.8 vs. 22 and 6.5 months for the intermediate and poor risk groups, respectively (p=0.179). Multivariate analysis for OS revealed that more than 2 metastatic sites (p=0.025) and clear cell histology (p=0.015) were predictors of poor and improved survival, retrospectively.
Conclusions: The results of this study revealed that patients with metastatic clear cell RCC outside the context of a randomized clinical study confirmed the efficacy and safety of pazopanib used as a first-line treatment in real-life conditions.
Key words: pazopanib, renal cell carcinoma, MSKCC risk stratification, real-life data, side effects.
Full Text: PDF